Get the Stockscreener App
147.00
0.46%
0.68
After Hours:
147.00
Insmed Inc stock is traded at $147.00, with a volume of 1.94M.
It is up +0.46% in the last 24 hours and down -6.46% over the past month.
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.
See More
Previous Close:
$146.32
Open:
$145.83
24h Volume:
1.94M
Relative Volume:
0.68
Market Cap:
$31.69B
Revenue:
$606.42M
Net Income/Loss:
$-1.28B
P/E Ratio:
-22.96
EPS:
-6.403
Net Cash Flow:
$-997.58M
1W Performance:
-7.33%
1M Performance:
-6.46%
6M Performance:
+2.44%
1Y Performance:
+92.69%
1-Day Range:
$143.76
$148.31
1-Week Range:
$143.76
$161.13
52-Week Range:
$60.40
$212.75
Insmed Inc Stock (INSM) Company Profile
Name
Insmed Inc
Sector
Industry
Phone
908-977-9900
Address
700 US HIGHWAY 202/206, BRIDGEWATER, NJ
Compare INSM vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INSM
Insmed Inc
|
147.00 | 31.54B | 606.42M | -1.28B | -997.58M | -6.403 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.27 | 123.47B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
766.66 | 83.60B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
748.72 | 46.83B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
318.65 | 43.11B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
297.04 | 34.79B | 5.36B | 287.73M | 924.18M | 2.5229 |
Insmed Inc Stock (INSM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-26 | Initiated | Barclays | Overweight |
| Jan-23-26 | Initiated | Roth Capital | Buy |
| Dec-19-25 | Resumed | Truist | Buy |
| Dec-04-25 | Initiated | Rothschild & Co Redburn | Buy |
| Oct-28-25 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-20-25 | Initiated | Wells Fargo | Overweight |
| Aug-20-25 | Initiated | William Blair | Outperform |
| Aug-13-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| May-13-25 | Initiated | Jefferies | Buy |
| Feb-25-25 | Initiated | RBC Capital Mkts | Outperform |
| Apr-23-24 | Initiated | Truist | Buy |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Jul-26-23 | Initiated | Guggenheim | Buy |
| Dec-09-22 | Initiated | Mizuho | Buy |
| Dec-07-22 | Initiated | Barclays | Overweight |
| Nov-18-22 | Initiated | BofA Securities | Buy |
| Apr-27-22 | Initiated | Goldman | Buy |
| Dec-06-21 | Initiated | JP Morgan | Overweight |
| Oct-19-21 | Resumed | Monness Crespi & Hardt | Buy |
| Oct-19-21 | Resumed | Morgan Stanley | Overweight |
| Oct-08-21 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Dec-17-20 | Initiated | Berenberg | Buy |
| Oct-12-20 | Resumed | Stifel | Buy |
| Sep-03-19 | Initiated | Goldman | Buy |
| Apr-09-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-15-19 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Jan-17-19 | Upgrade | Goldman | Neutral → Buy |
| Jan-02-19 | Initiated | Canaccord Genuity | Buy |
| Aug-06-18 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jul-23-18 | Initiated | Goldman | Neutral |
| Apr-23-18 | Upgrade | Credit Suisse | Neutral → Outperform |
| Mar-21-18 | Initiated | Morgan Stanley | Overweight |
| Jan-18-18 | Initiated | Credit Suisse | Neutral |
| Sep-05-17 | Reiterated | Evercore ISI | Outperform |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Jul-11-17 | Initiated | Robert W. Baird | Outperform |
| Mar-15-16 | Initiated | Stifel | Buy |
| Nov-09-15 | Downgrade | UBS | Buy → Neutral |
| Oct-06-15 | Reiterated | H.C. Wainwright | Buy |
| Jun-09-15 | Initiated | Citigroup | Neutral |
| Mar-26-14 | Reiterated | HC Wainwright | Buy |
View All
Insmed Inc Stock (INSM) Latest News
Insmed, Inc. $INSM Shares Sold by Rafferty Asset Management LLC - MarketBeat
Insmed Incorporated (INSM): Investor Outlook Reveals A Promising 42% Upside - DirectorsTalk Interviews
INSM Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Assessing Insmed (INSM) Valuation After Recent Share Price Weakness And Brensocatib Launch Expectations - Yahoo Finance
Insmed at TD Cowen Conference: Strategic Growth and Market Expansion - Investing.com India
William Blair Investment Management LLC Has $223.94 Million Stock Holdings in Insmed, Inc. $INSM - MarketBeat
Insmed Incorporated (INSM) Enters 2026 With Momentum - Finviz
Insmed (INSM) director gifts shares and details family holdings - Stock Titan
Insmed, Inc. Experiences Revision in Its Stock Evaluation Amid Financial Performance Trends - Markets Mojo
Artisan Partners Limited Partnership Grows Stock Position in Insmed, Inc. $INSM - MarketBeat
Why Insmed Incorporated (INSM) is One of the Best Strong Buy Healthcare Stocks to Invest In - Finviz
Westfield Capital Management Co. LP Lowers Stock Holdings in Insmed, Inc. $INSM - MarketBeat
Thornburg Investment Management Inc. Trims Holdings in Insmed, Inc. $INSM - MarketBeat
Insmed Stock Hits Day Low of $148.24 Amid Price Pressure - Markets Mojo
INSMED Chief Legal Officer Sells Shares Worth Over $3.8 Million - TradingView
Insmed (INSM) CLO exercises options and sells 24,774 shares - Stock Titan
Insmed (INSM) Q4 2025 Earnings Call Transcript - AOL.com
HC Wainwright Forecasts Insmed's Q3 Earnings (NASDAQ:INSM) - MarketBeat
Brown Advisory Small-Cap Growth Fund's Insmed Inc(INSM) Holding History - GuruFocus
INSM (NASDAQ: INSM) reports Michael Smith sales and issuer plan issuances - Stock Titan
Analysts Are Bullish on Top Healthcare Stocks: Travere Therapeutics (TVTX), Insmed (INSM) - The Globe and Mail
H.C. Wainwright Remains a Buy on Insmed (INSM) - The Globe and Mail
INSM Stock Rating: Mizuho Lowers Price Target Amid Consistent Ou - GuruFocus
Mizuho Issues Pessimistic Forecast for Insmed (NASDAQ:INSM) Stock Price - MarketBeat
Insmed Incorporated (INSM) Gained from Its Lead Product ARIKAYCE - Yahoo Finance
HC Wainwright Comments on Insmed's Q1 Earnings (NASDAQ:INSM) - MarketBeat
Insmed chair and CEO Lewis sells $1.6m in stock By Investing.com - Investing.com Nigeria
Insmed chair and CEO Lewis sells $1.6m in stock - Investing.com
Insmed (INSM) Is Up 6.9% After BRINSUPRI Sales Beat Expectations And 2026 Target SetWhat's Changed - Yahoo Finance
H.C. Wainwright reiterates Buy on Insmed stock, $230 target By Investing.com - Investing.com UK
William Lewis Sells 10,699 Shares of Insmed (NASDAQ:INSM) Stock - MarketBeat
Insmed (INSM) CEO Lewis exercises options and sells 10,699 shares - Stock Titan
INSM: HC Wainwright & Co. Reiterates Buy Rating with $230 PT | I - GuruFocus
Mizuho Securities Cuts Insmed Price Target to $204 From $211, Maintains Outperform Rating - marketscreener.com
Insmed (NASDAQ:INSM) Given Buy Rating at HC Wainwright - MarketBeat
H.C. Wainwright reiterates Buy on Insmed stock, $230 target - Investing.com
Patient Square Capital LP Reduces Stock Holdings in Insmed, Inc. $INSM - MarketBeat
Insmed Gets UK Marketing Authorization for Non-Cystic Fibrosis Bronchiectasis Treatment - marketscreener.com
Hillsdale Investment Management Inc. Sells 7,000 Shares of Insmed, Inc. $INSM - MarketBeat
Bank of America Securities Reaffirms Their Buy Rating on Insmed (INSM) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Talkspace (TALK) and Insmed (INSM) - The Globe and Mail
Wells Fargo Lowers Price Target for Insmed (INSM) Amid Overweigh - GuruFocus
Breaking Down Insmed: 16 Analysts Share Their Views - Benzinga
Wall Street Analysts Think Insmed (INSM) Could Surge 33.6%: Read This Before Placing a Bet - Finviz
Insmed Lags on Q4 Earnings, Stock Gains on 2026 Brinsupri Sales View - Bitget
Insmed Q4 Reinforces Confidence in Brinsupri Growth, RBC Says - marketscreener.com
Insmed May Top Revenue Target for Bronchiectasis Drug Brinsupri, Morgan Stanley Says - marketscreener.com
Insmed Incorporated (NASDAQ:INSM) Q4 2025 Earnings Call Transcript - Insider Monkey
Skandinaviska Enskilda Banken AB publ Grows Position in Insmed, Inc. $INSM - MarketBeat
Morgan Stanley Lifts Price Target on Insmed to $166 From $162, Keeps Equalweight Rating - marketscreener.com
Insmed, Inc. $INSM Shares Sold by BNP PARIBAS ASSET MANAGEMENT Holding S.A. - MarketBeat
Insmed Inc Stock (INSM) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.51%
0.02%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):